The Alternatives to Carcinogenicity Testing Committee of the International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) conducted a large-scale, multinational collaborative research program to evaluate several genetically-modified mouse assays for assessing the human carcinogenic potential of compounds. The data from this testing program have made an important contribution to the general understanding of how these models can be best applied in hazard identification; however, questions still exist regarding methodology and data interpretation. To address these issues, ILSI HESI hosted a February 2003 workshop on the Utility of Transgenic Assays for Risk Assessment. The purpose of this workshop was to reach an understanding of how data from genetically-modified mouse models are viewed by different regulatory bodies in the pharmaceutical sector, and based on this understanding, to identify areas in which more experimental work may be needed to increase the utility of data derived from these assays. In the course of discussions, various data gaps related to model selection and protocol issues were identified. Based on the outcome of the workshop, various studies are proposed to provide data to improve the utility of currently available assays for cancer hazard identification and risk assessment purposes.
Introduction
In 1996, the International Conference on Harmonization (ICH) Expert Working Group on Safety acknowledged the limited utility of conventional two-year rodent bioassays for assessing the human carcinogenic potential of chemicals, including pharmaceuticals, based on past positive findings that are now considered to have little or no relevance for human risk assessment. The ICH further acknowledged the potential of several new testing models to produce meaningful information for human cancer risk assessment. The group proposed a new scheme for the carcinogenicity testing of pharmaceuticals (ICH S1B). This scheme calls for one long-term rodent carcinogenicity study, plus an additional test for carcinogenic activity in vivo, consisting of either another long-term carcinogenicity study in a second rodent species, or a short-or medium-term rodent test, to be chosen from several available alternative models.
This guideline opened the way for scientists to use greater flexibility and judgment in choosing an approach for assessing carcinogenic potential. It also stimulated international interest in gaining experience and a greater understanding of the available methodologies for carcinogenicity testing, as these new methods had not been fully characterized and scientific questions remained to be addressed regarding their most appropriate application. To address these issues, the International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) coordinated a large-scale, multinational collaborative research program to provide data needed to further understand the benefits and limitations of the proposed new models. Under the auspices of the ILSI HESI Alternatives to Carcinogenicity Testing (ACT) Committee, seven alternative models have been tested, including five genetically-modified mouse models:
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• Tg.rasH2 transgenic mouse model (multiple copies of the human c-Ha-ras gene inserted)
• Tg.AC transgenic mouse model (multiple copies of a zeta-globulin promoter/v-Ha-ras oncogene reporter construct inserted)
• p53 +/-knockout mouse model (one allele of the p53 tumor suppressor gene deleted)
• XPA -/-knockout mouse model (both alleles of a nucleotide excision repair gene deleted)
The results of this testing program, developed over four years, were previously discussed in Toxicological Sciences (Cohen et al., 2001 ), presented at a workshop, and as a special issue of Toxicologic Pathology (Vol. 29, supplement issue, 2001 ). This latter publication also contains comprehensive background information covering each of the alternative models. The ILSI HESI research program has added important new data to our understanding of how these models can be applied in assessing carcinogenic potential; however, questions still exist regarding how these models may best be used in a regulatory environment. To address these questions, the ILSI
HESI ACT Committee hosted a February 2003 workshop on the Utility of Transgenic Assays for
Risk Assessment in Washington, DC. This workshop involved approximately 75 participants from the U.S, Europe, and Japan, including scientists from industry, government, and academia.
The purpose of the workshop was to reach an understanding of how data from geneticallymodified mouse models are viewed by different regulatory bodies, and based on this -4 -understanding, identify areas in which more experimental work may be needed to increase the utility of data derived from these assays.
Regulatory Perspectives
Perspectives of U.S., European, and Japanese regulatory agencies regarding the use of genetically-modified assays for carcinogenic risk assessment, as expressed at the ILSI HESI ACT Workshop, are described below.
United States Food and Drug Administration (U.S. FDA)
Over the past two years, 25% of the proposed mouse carcinogenicity study protocols received by without papilloma formation, and examples of papillomas formed without preceding dermal irritation or inflammation. The apparent inability of the Tg.AC assay to distinguish nongenotoxic "promoters" from "complete" genotoxic carcinogens complicates the integration of this assay with results from traditional carcinogenicity assays and other data.
FDA experience with the Tg.rasH2 assay has been too limited to comment on here, although this assay is generally viewed as acceptable for carcinogenicity testing, based on the results of the ILSI HESI research program evaluation of this assay.
-6 -Results from these alternative studies have helped alleviate concern when the adequacy of a traditional two-year study was questionable and repeating the two-year study was undesirable to both the drug sponsor and the FDA. Results have also helped alleviate concern when the traditional two-year rat study was adequate, but the findings were equivocal. Results from these assays have been used as a part of the weight of evidence in early assessment of genotoxicity study results before initiation of clinical trials. It should also be noted that results from genetically-modified and other alternative assays should not be used in isolation, but rather, integrated with all available toxicology and pharmacology data, and results from traditional carcinogenicity assays done in rats.
European Committee for Proprietary Medicinal Products Safety Working Party (CPMP SWP)
The following conclusions and recommendations are based on a comprehensive review by the CPMP SWP of the data produced from the ILSI HESI research program. Both the Tg.rasH2 and the p53 +/-models are considered to be acceptable for regulatory use and likely to have an additive value to carcinogenicity assessment if the experiment is properly designed. The available data do not suggest that one model is more appropriate than another for a particular class of compounds, a particular mechanism of tumorigenic activity, or other specific conditions.
It should be noted that these genetically-modified models can also be used as an additional component in the assessment of potential genotoxic carcinogenicity. However, the outcome of an experiment with genetically-modified animals should not be considered as THE decisive factor in the assessment of genotoxicity, but rather, as part of the weight of evidence in this assessment.
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The Tg.AC model reacts inconsistently and incompletely to known human carcinogens.
Although developed to be responsive at the site of application (i.e., the skin), the evaluation of studies using human carcinogens has included responses at other sites as well in accordance with the profile of the compound. Nevertheless, the model is considered to be useful for screening the carcinogenic properties of dermally administered pharmaceuticals. The Tg.AC model cannot be recommended for oral studies with the forestomach as the reporter site. The XPA -/-and XPA -/-/p53 +/-assays appear to be promising models, but more data from studies using acceptable protocols are needed.
As part of the above evaluation of alternative models, several points were raised regarding experimental design:
1. The number of animals per group used in the ILSI HESI studies was too small, which sometimes hampered study interpretation. It is recommended that group size be increased to 20-25 animals per sex per group.
2. If a positive study outcome is defined on the basis of the "rare tumor criteria" only, a repetition of the study should be considered (especially when the historical control data on which the definition of a "rare tumor" is based are relatively limited).
3. Wild type animals should be included (except in the Tg.AC assay), preferably as control and high dose groups, in order to determine whether the outcome in genetically-modified animals is a function of the modified genotype. This would provide additional and useful mechanistic information.
-8 -4. At present, positive controls should be included in the p53 +/-and Tg.rasH2 models. As an alternative, approaches to verify the genotype of the test animals at a molecular level may be acceptable in the future.
The regulatory experience gathered in the European system consists mainly of requests for advice regarding study design and discussions with companies about the potential acceptability of such a test in the non-clinical package for a marketing authorization. As time progresses, it is anticipated that companies will include the results of these studies in their marketing authorization applications.
In Europe, companies can come to the European Agency for the Evaluation of Medicinal Products (EMEA) for advice with respect to their product safety-testing plan, including set-up of carcinogenicity testing assays. While the ILSI HESI program was underway, three requests for advice were received, all regarding the applicability of newborn mice. The CPMP accepted all three proposals; however, it became clear later on that the FDA had expressed a different opinion in various cases, mainly because of genotoxicity testing data. Following completion of the ILSI HESI research project, the CPMP received four specific requests for advice regarding the p53 +/-model. Issues related to how to handle estrogenic hormones, and the tissue specificity of the model.
Thus far, five product applications received for marketing authorization of new active substances include studies with p53 +/-mice in their dossiers; all five studies showed negative results for carcinogenicity. These studies were accepted as contributing to the weight of -9 -evidence, in combination with results from the long-term rat study (available for 4/5 products) and data from the genotoxicity tests. A Tg.rasH2 study was also included in a dossier for which a p53 +/-study was already present. The company carried out this additional study because of lack of experience with the p53 +/-model with regard to compounds that may be specifically carcinogenic in the gastrointestinal tract. Finally, in a dossier of an orally-administered compound, a dermal Tg.AC study was included. This study was not accepted as contributing to the weight of evidence, as the route of administration was considered to be inappropriate, and the study did not add to the body of information regarding the mechanism of tumor formation in the rat.
To conclude,
• The p53 +/-and Tg.rasH2 mice are suitable models for testing conventional chemical entities.
Tg.AC mice should be used for dermally applied products only.
• The study design of the various models should be adapted in various aspects to be suitable for robust regulatory use.
The experience obtained in the European system thus far is insufficient to allow for further conclusions.
Japanese Ministry of Health, Labor, and Welfare (MHLW) 1
Current regulatory requirements allow for the use of an alternative assay, in combination with a traditional 2-year assay, to assess a compound's human carcinogenic potential. In choosing a genetically modified animal model for assessing carcinogenic potential, it is important to consider the model's underlying mechanism of action and phenotypic characteristics. In general,
-10 -the Tg.rasH2 model responds well to both genotoxic and non-genotoxic carcinogens, the p53 +/-model is most responsive to complete carcinogens, and the Tg.AC model is of limited use due to its limited phenotype.
The general testing scheme for use of alternative carcinogenicity assays will depend on the compound's mutagenicity. A mutagenic compound is evaluated using a multi-organ assay system, such as the p53 +/-or Tg.rasH2 model, which can detect complete genotoxic carcinogens.
The compound should also be tested in an assay, such as the Muta Tm mouse or Big-Blue Tm , which predicts the target tissues of effect, before being evaluated in a model aimed at assessing these specific target tissues (e.g., XPA -/-for skin or oral tissues, Tg.rasH2 for lung).
The p53 -/-model is being used in studies conducted at the Japanese National Institute of Health Sciences (NIHS) aimed at understanding mechanisms of carcinogenesis, with emphasis on doseresponse relationships and discerning possible thresholds. Additionally, researchers at NIHS are working towards developing a p53 -/-model on a C3H/He background that might be capable of responding to genotoxic carcinogens within ten weeks of treatment.
Assays for evaluating the carcinogenic potential of non-mutagenic compounds are not readily available at this time. For now, a non-mutagenic compound should be evaluated in a multi-organ system, such as the Tg.rasH2, which can detect compounds acting through epigenetic mechanisms. In the future, the compound should also be evaluated using a cDNA microarray assay to predict possible target tissues, and then examined using a specific target tissues model.
Areas of Agreement and Disagreement in Perspectives
To fulfill the objectives of the workshop, it was considered instructive to make a side-by-side comparison of the views expressed concerning the utility of each of the alternative models. Tg.AC Model: CPMP considers this model to be useful for screening the carcinogenic potential of dermally administered pharmaceuticals. In agreement with CPMP, FDA considers this model useful for dermally applied products; however, some data from products intended for systemic administration, but assayed using the dermal route in the Tg.AC model, have been reviewed.
NIHS expressed concerns regarding the stability of this model's phenotype.
XPA -/-
, and XPA -/-/p53 +/-models: CPMP expressed the view that these models, while promising, require further development. For example, additional studies using known human carcinogens should be conducted. Neither FDA nor NIHS appear to have experience with these models.
-12 -Neonatal Mouse Model: CPMP has accepted proposals for the use of this model. FDA considers this to be an appropriate model in select limited circumstances for compounds that are clearly or equivocally genotoxic. NIHS has some experience with this model.
There is a need for further discussion to resolve differences between the CPMP and FDA concerning the acceptability of the p53 +/-model for genotoxic versus non-genotoxic compounds.
The FDA reserves the use of this model for compounds that are clearly or equivocally genotoxic, while CPMP considers the model acceptable for regulatory purposes without stipulating that the compound in question be shown to have genotoxic potential. In this context, it is important to note that the p53 +/-model is considered inappropriate as a test for genotoxicity as such, but rather, to establish potential carcinogenicity.
Overall, the above perspectives show that there is now widespread agreement that alternative assays can and, indeed, do play an important role in carcinogen safety assessment. Importantly, general thinking has advanced beyond the notion that the traditional standard approach involving two species of rodent of both sexes exposed over their lifetimes is the only way to assess the carcinogenic potential of compounds in vivo. It is now evident that alternative models can be used as an integral component of an overall evaluation of carcinogenic potential. In addition, the above perspectives also indicate that there are potential areas in which more study of alternative models would be beneficial. Having reached an understanding of how these assays are currently used in safety risk assessment, it is important to consider some of the issues related to their use.
Such an exercise will help to elucidate what the data gaps are for these assays and what additional studies may be done to increase their utility.
It is also noted that, at least in the U.S., the greatest amount of regulatory experience has been associated with the p53 +/-model. Regulatory bodies, however, express disparate views regarding the application of this model for risk assessment purposes. Specifically, the U.S. and Japan consider the p53 +/-model acceptable for the testing of compounds shown to be clearly or equivocally genotoxic only; however, European regulatory bodies consider this model acceptable for all compounds.
In addition to general agreement regarding the utility of the p53
, Tg.rasH2, and Tg.AC models, a number of the general aspects of study design are also accepted. However, a number of specific details regarding group size, study duration, and data interpretation are under discussion.
While it is generally accepted that group sizes should be increased to 20-25 animals per sex per dose group, the single most important outstanding issue is the duration of the p53 +/-assay. It is not known from presently available data whether an increase in duration of this assay from six to nine months would enhance the utility of the data derived.
In the course of discussions, the following data gaps related to assay selection and/or protocol issues have been identified for which more experimentation could be of value in increasing the utility of genetically-modified mouse assays for risk assessment:
• Study duration Additionally, it is noted that experience with alternative testing methods remains limited, which in turn, affects the decision to test for carcinogenic potential using these methods versus the traditional two-year rodent bioassay. Experimental work examining some of the above issues would assist in the evaluation of criteria by which specific assays are selected. For example, in order to address whether genotoxic potential should be considered in the selection of an assay (in particular, the p53 +/-model), it would be useful to test more clastogenic compounds in this assay.
The answer to the question of which alternative model to use will also become more clear as experience with the models grows.
Although further work is needed in the development of additional alternative models, the consensus from this workshop is that efforts should be focused on addressing some of the issues related to the more widely-used alternative assays. In particular, questions related to the p53 +/-and Tg.rasH2 models are considered the most important to address at this time.
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